Search
Cholic Acid
go.drugbank.com/drugs/DB02659ApprovedInvestigationalA major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.
Bisegliptin
go.drugbank.com/drugs/DB06127InvestigationalIt is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion
Unoprostone
go.drugbank.com/drugs/DB06826ApprovedWithdrawnUnoprostone isopropyl is a prostaglandin analogue. Ophthalmic Solution 0.15% is a synthetic docosanoid. Unoprostone isopropyl has the chemical name isopropyl (+)-(Z)-7-[(1R,2R,3R,5S)-3,5 dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-heptenoate....
Pucotenlimab
go.drugbank.com/drugs/DB17552ApprovedInvestigationalIt received its first global approval in China in July 2022 for the treatment of solid tumours.[A257296] It is being investigated in other cancers.
Denatonium
go.drugbank.com/drugs/DB18588InvestigationalSynonyms: Benzenemethanaminium, n-(2-((2,6-dimethylphenyl)amino)-2-oxoethyl)-n,n-diethylCategories: Compounds used in a research, industrial, or household settingTofisopam
go.drugbank.com/drugs/DB08811InvestigationalThe D-enantiomer ([dextofisopam]) is currently in phase II trials in the U.S. for the treatment of irritable bowel syndrome. … Although Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe.
XTL-6865
go.drugbank.com/drugs/DB06058InvestigationalXTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.
Barnidipine
go.drugbank.com/drugs/DB09227Investigationalafter a 1-year and 2-year follow-up period in 91% of the patients who had an initial response to the drug [A7842]. … It is available in modified-release oral tablets under the brand name Vasexten to be taken once daily in the morning.
DP-b99
go.drugbank.com/drugs/DB05820InvestigationalDP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment
Oxolamine
go.drugbank.com/drugs/DB13216ApprovedOxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant [L5416]. It is listed as a prescription drug in New Zealand legislation [L5419]. … Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation [L5422].